Novo detemir approval timeline
Executive Summary
Novo-Nordisk expects mid-2005 approval for long-acting insulin analog detemir following submission of additional data to FDA, CEO Lars Rebien Sorensen says. FDA requested more clinical information in Oct. 7 "approvable letter" (1"The Pink Sheet" Oct. 13, 2003, In Brief). Novo believes the request can be met through a "short-term" PK/PD study to assess ethnic differences between patients and data from an ongoing trial...
You may also be interested in...
Novo detemir “approvable”
Novo Nordisk receives "approvable" letter for its long-acting insulin analog insulin detemir Oct. 7...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.